[Feminizing syndrome].
Hayashi
Yutaro
Y
Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences.
Kojima
Yoshiyuki
Y
Kohri
Kenjiro
K
D000726:Androgen Antagonists / Q000009:adverse effects; D000728:Androgens / Q000378:metabolism; D042944:Cholestenone 5 alpha-Reductase / Q000172:deficiency; D003937:Diagnosis, Differential; D004054:Diethylstilbestrol / Q000009:adverse effects; D004967:Estrogens / Q000378:metabolism; D005262:Feminization / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006111:Graves Disease / Q000150:complications; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D011379:Prognosis; D011944:Receptors, Androgen / Q000235:genetics; D006435:Renal Dialysis / Q000009:adverse effects; D013577:Syndrome; D013736:Testicular Neoplasms / Q000150:complications / Q000378:metabolism
D000726:Androgen Antagonists; D000728:Androgens; D004967:Estrogens; D011944:Receptors, Androgen; D004054:Diethylstilbestrol; D042944:Cholestenone 5 alpha-Reductase